Biomarin Pharmaceutical (BMRN) Net Cash Flow Growth (1y) (2010 - 2026)
Biomarin Pharmaceutical (BMRN) Net Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 11.69 Bn | 9.46 Bn | 571.21 Mn | 1,538.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,538.48% |
| Dec 31, 2025 | -77.22% |
| Sep 30, 2025 | 112.10% |
| Jun 30, 2025 | -24.24% |
| Mar 31, 2025 | 1,167.58% |
| Dec 31, 2024 | 1,094.33% |
| Sep 30, 2024 | -429.89% |
| Jun 30, 2024 | 98.87% |
| Mar 31, 2024 | 93.05% |
| Dec 31, 2023 | 28.11% |
| Sep 30, 2023 | -37.48% |
| Jun 30, 2023 | 656.46% |
| Mar 31, 2023 | -947.55% |
| Dec 31, 2022 | -24.16% |
| Sep 30, 2022 | 698.12% |
| Jun 30, 2022 | 155.60% |
| Mar 31, 2022 | -7.02% |
| Dec 31, 2021 | 91.90% |
| Sep 30, 2021 | -112.14% |
| Jun 30, 2021 | -107.74% |